The use of cannabinoids in the medical world is increasingly recognized. Their association with chemical supplements helps to relieve the side effects induced, and also to reduce the harmful impact of certain supplements on the body. Cannabinoids & opiates: positive association to reduce neuropathy induced by chemotherapy.
Recently , a study was conducted and published in December 2019 by a team of scientists from the Department of Pharmacological Sciences at the Icahn School of Medicine on Mount Sinai, New York, USA. You can, of course, consult it by clicking on this link.
So , this study in mice showed that the chemotherapeutic agent paclitaxel-induced peripheral neuropathy during chemotherapy. In other words, this molecule used to initiate chemotherapy can cause the development of peripheral neuropathic pain.
Indeed , according to feedback from the study, this symptom could be treatable by targeting the heteromers of the CB1 receptor and the delta-opioid receptor.
A combination of very low doses of a cannabinoid (HU-210) and an opioid (SNS80) is very effective in releasing the mechanical allodynia (pain following non-painful stimulation) caused by this peripheral neuropathy.
In summary, the combination of cannabinoids and opiates shows to reduce the sensation of pain perceived by the patients concerned, following the implementation of this chemotherapy.
Taken together, these results imply that CB1R-DOR heteromers upregulated during mechanical allodynia associated with CIPN could serve as a potential target for the treatment of neuropathic pain, including CIPN.